In conclusion, this study shows that primary and long-term cultured ovarian cancer cells are largely resistant to anti-EGFR-targeted therapies, which correlates with the limited efficacy of clinical studies evaluating anti-EGFR-substances in ovarian cancer [8,10,13,17]. Here, EGFR is linked to ovarian carcinoma.